Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Drug composition containing irbesartan and hydrochlorothiazide

A technology of hydrochlorothiazide and irbesartan, which is applied in the field of pharmaceutical preparations, can solve the problems that there are no reports on the use of hydrochlorothiazide in low-dose irbesartan, and there are no literature reports on hydrochlorothiazide serum C-reactive protein, so as to reduce cardiovascular morbidity and death rate, good prognosis, and improved prognosis

Active Publication Date: 2013-04-17
NANJING CHIA TAI TIANQING PHARMA
View PDF7 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] To sum up, although there have been many reports on the combined application of irbesartan and hydrochlorothiazide to have a synergistic antihypertensive effect, all the reports are on the combined application of irbesartan and low-dose hydrochlorothiazide, and there is no report on the combination of irbesartan and hydrochlorothiazide. The use of low-dose irbesartan has been reported, and there is no literature report that hydrochlorothiazide combined with low-dose irbesartan can be used to reduce the risk of elevated serum C-reactive protein (CRP) in hypertensive patients

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Drug composition containing irbesartan and hydrochlorothiazide
  • Drug composition containing irbesartan and hydrochlorothiazide
  • Drug composition containing irbesartan and hydrochlorothiazide

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0018]

[0019] Preparation process: first put hydrochlorothiazide and starch into a mortar, grind and mix uniformly, sequentially add sodium carboxymethyl starch, microcrystalline cellulose and mix well, finally add irbesartan and mix well, use 5% PVP in anhydrous ethanol solution Used as a binder to make wet granules, dried at 40°C, granulated, mixed with magnesium stearate, and pressed into tablets.

Embodiment 2

[0021]

[0022]

[0023] Preparation Process:

[0024] Pass the irbesartan, hydrochlorothiazide, lactose, microcrystalline cellulose and cross-linked polyvinylpyrrolidone in the prescription through a 100-mesh sieve, mix well, add 10% starch slurry to granulate, dry below 60℃, 18-mesh sieve Whole granules, add the prescribed amount of magnesium stearate, mix well, and compress the tablets.

Embodiment 3

[0026]

[0027] Preparation Process:

[0028] Pass the irbesartan, hydrochlorothiazide, starch, mannitol and L-HPC in the prescription through a 100-mesh sieve, mix them well, add 10% starch slurry to granulate, dry below 50℃, 18-mesh sieve, and add to the prescription The amount of magnesium stearate is mixed well and compressed into tablets.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a drug composition containing irbesartan and hydrochlorothiazide. The drug composition is prepared into a tablet or a capsule by wet granulation of an active ingredient and a pharmaceutic adjuvant; the active ingredient comprises irbesartan and hydrochlorothiazide at a weight ratio of 1:(1.3-10); and the pharmaceutic adjuvant comprises a filler, a disintegrating agent, adhesive and a lubricant. With the adoption of the drug composition, impaired glucose tolerance is alleviated, the biological activity of insulin resistance is prevented, rising of a C-reactive protein level of a patient with hypertension can be prevented, the morbidity and mortality of and caused by various cardiovascular diseases in the future are reduced, and the drug composition has a very good improvement effect on the prognoses of the patient with the hypertension.

Description

Technical field [0001] The invention belongs to the technical field of pharmaceutical preparations, and specifically relates to a pharmaceutical composition containing irbesartan and hydrochlorothiazide. Background technique [0002] The occurrence of hypertension is caused by various factors such as hyperactivity of the sympathetic nervous system, renal water and sodium retention, and activation of the renin-angiotensin-aldosterone system (RAAS). The existing antihypertensive drugs can only target one disease The mechanism works, and the effective rate of any antihypertensive drug is only 25%-50%. In order to effectively control blood pressure, 70% of hypertensive patients need to use antihypertensive drugs in combination. The 2007 European Society of Hypertension (ESH) / European Society of Cardiology (ESC) Hypertension Guidelines pointed out that the initial blood pressure is 2nd and 3rd grade hypertension, and the blood pressure is normal, but patients with high or extremely hi...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/549A61K31/4184A61P9/12
Inventor 袁红波章晓骅
Owner NANJING CHIA TAI TIANQING PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com